ClinicalTrials.gg
RecruitingNCT07040592HARPUpdated Mar 24, 2026

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide

A Phase 2 interventional study of semaglutide in Alcohol Use Disorder (AUD) and HIV, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Yale University · Phase 2, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies testing semaglutide in Alcoholism — 6 open to participants now, 8 under way, 2 of them phase 3. Semaglutide · Alcoholism.

Planned enrollment
11th of 12
30 · median 64
Started
2026
with 5 others
Phase 2
7 of 12
2 open now
Registered
7th of 12
by date
Lead sponsor
3 of 12
Yale University

Among the 12 studies testing semaglutide in Alcoholism, this one is the 11th largest by planned enrollment, is one of 6 that started in 2026, is one of 7 in phase 2, and was the 7th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

6 of the 12 studies testing semaglutide in Alcoholism are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing semaglutide in Alcoholism, or all of them as a file.
02

Study summary

This study seeks to determine the feasibility, acceptability, and preliminary efficacy of an intervention consisting of off-label use of a medication with strong efficacy data for alcohol use disorder (AUD) with medical management and a clinical pharmacist-delivered behavioral intervention in reducing alcohol use among individuals with HIV and AUD.

Read the detailed description

This is a series of three open-label pilot studies that consist of a 12-week intervention including off-label use of medication with MM and a clinical pharmacist-delivered behavioral intervention to treat AUD. Participants will receive counseling that incorporates brief feedback and advice with motivational enhancement techniques to assist the participant in changing their behaviors with respect to alcohol consumption and/or polypharmacy defined as taking five or more medications, particularly if those medications interact with alcohol.

In addition, participants will be offered semaglutide in the third pilot study. The rationale for utilizing an open-label pilot study design is to determine the feasibility, acceptability, safety, and preliminary efficacy of this intervention for the management of AUD. Participants will be interviewed with regards to their perspectives on feasibility and acceptability. They will be instructed to have medication bottles at study visits to assess medication adherence and will be assessed with readiness to change metrics and questions regarding quantity and frequency of alcohol use. Patients will also be asked to complete an AUDIT-C screen and the Alcohol Symptom Checklist at the start of the study period to screen for mild, moderate, or severe AUD. Several assessments including interviews and laboratory testing will be done at study visits.

03

Conditions studied

  • Alcohol Use Disorder (AUD)
  • HIV

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed with
  • Receive care at the Atlanta VA Healthcare System
  • Age 18 or over
  • Meet criteria for mild, moderate, or severe alcohol use disorder by the Alcohol Symptom Checklist and the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) screen
  • Have evidence of significant alcohol use: PEth > 20ng/ml
  • Prescribed >=5 medications
  • Have cell phone or reliable contact number
  • Can provide written

Exclusion criteria

Exclusion Criteria:

  • Active engagement in formal alcohol treatment including medications for alcohol use disorder at the time of enrollment
  • Self-report or laboratory test confirming pregnancy, nursing, or trying to conceive
  • Life-threatening or unstable medical, surgical, or psychiatric condition that prohibits participation (including current or past intent to harm oneself or others within the prior 12 months and not receiving treatment)
  • Untreated moderate to severe opioid use disorder
  • Residence out of state
  • Inability to read or understand English
  • History of serious or adverse reaction to study medication
  • Taking potentially interactive medication(s) for diabetes
  • \<23
  • Diagnosis of type 1 Diabetes
  • Personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, Severe gastrointestinal dysmotility, including gastroparesis, History of pancreatitis (does not pertain to patients for whom the cause of pancreatitis is known and no longer presents a risk), severe gallbladder disease
  • Known Proliferative Diabetic Retinopathy, severe Non-Proliferative Diabetic Retinopathy, Macular Edema, or Cystoid Macular Edema
  • Already prescribed the pilot medication at the time of study recruitment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Semaglutide

    Participants will receive a prescription for semaglutide.

    Drug: semaglutide

Interventions

  • All participants will receive a prescription for semaglutide and will meet with a clinical pharmacist and addiction psychiatrist for further support

06

What researchers measure

Primary outcomes

  1. Proportion of participants who complete enrollment and duration of sessions

    Proportion of participants who complete enrollment and duration of sessions to assess feasibility of study

    Time frame: 12 weeks

  2. Number of sessions completed

    Number of sessions completed to assess acceptability of study

    Time frame: 12 weeks

  3. Adherence to Medication

    Medication adherence will be measured by the number of prescriptions filled by electronic health record to assess acceptability of study

    Time frame: 12 weeks

  4. Safety of study assessed by adverse event reporting

    Safety will be assessed by the percentage of study participants who report adverse events.

    Time frame: 12 weeks

Secondary outcomes

  1. Efficacy of study - change in self-reported alcohol use

    Change in self-reported alcohol use (# of days of alcohol use and # of drinks per day) on the Timeline Followback.

    Time frame: 12 weeks

  2. Efficacy of study - change in PEth (phosphatidylethanol) results

    PEth is a biomarker for alcohol consumption. Change in PEth result from baseline PEth levels.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.

Of 123 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 17 months is below that.

Counting every sponsor, half of 135 studies reached it within 33 months; a quarter within 21 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2025
First posted
Jun 27, 2025
StartActual
Jan 15, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07040592
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Jun 27, 2025
Start date
Jan 15, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Mar 24, 2026

Study contacts

E. Jennifer Edelman, MD, MHS
Contact
ejennifer.edelman@yale.edu
203-737-7115
June-Marie Weiss, MA, MEd
Contact
junemarie.weiss@yale.edu
203-737-3347
E. Jennifer Edelman, MD, MHS
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion